Device Trial Radar · NCT03604263
ArcticLine Feasibility Study
Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Oct 18, 2018
Primary completion
Nov 18, 2019
Study completion Nov 18, 2019
Sponsor
- Lead sponsor
- Medtronic Cardiac Ablation SolutionsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jul 27, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the ArcticLine Feasibility Study is to collect preliminary safety and effectiveness data on the ArcticLine Catheter.
Conditions
- Atrial Fibrillation
- Atrial Flutter
Interventions
ArcticLine Cardiac Cryoablation CatheterDevice
Cryoablation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Primary Safety Events With an Onset Date Within 7 Days Post-procedure.Time frame: 7 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
BayCare Medical Group Cardiology
Tampa, Florida
University of Michigan
Ann Arbor, Michigan
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.